LUCC: Lund University Cancer Centre
221 – 230 of 2748
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Mini-heterochromatin domains constrain the cis-regulatory impact of SVA transposons in human brain development and disease
2024) In Nature Structural & Molecular Biology(
- Contribution to journal › Article
-
Mark
Myocardin related transcription factor and galectin-3 drives lipid accumulation in human blood vessels
(
- Contribution to journal › Article
-
Mark
Neuropathological findings in Down syndrome, Alzheimer's disease and control patients with and without SARS-COV-2 : preliminary findings
(
- Contribution to journal › Article
-
Mark
Importance of resection margin after resection of colorectal liver metastases in the era of modern chemotherapy : population-based cohort study
(
- Contribution to journal › Article
-
Mark
Real-World Treatment Patterns and Survival Outcomes for Patients with Non-Metastatic Non-Small-Cell Lung Cancer in Sweden : A Nationwide Registry Analysis from the I-O Optimise Initiative
(
- Contribution to journal › Article
-
Mark
Response to Lao, Guan, Wang, et al.
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Predictive factors for recurrent acute appendicitis after conservative treatment
(
- Contribution to journal › Article
-
Mark
Discovery of the Selective and Orally Available Galectin-1 Inhibitor GB1908 as a Potential Treatment for Lung Cancer
2024) In Journal of Medicinal Chemistry(
- Contribution to journal › Article
-
Mark
Increased risk of venous thromboembolism in young and middle-aged individuals with hereditary angioedema : a family study
2024) In Blood(
- Contribution to journal › Article
-
Mark
Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE) : a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network
(
- Contribution to journal › Article